OvaScience Soars 35% Amid Positive Corporate Goals, Wedbush Upgrade
Shares of OvaScience Inc (NASDAQ: OVAS) soared over 35 percent Thursday following its announcement on Wednesday that it achieved its 2014 corporate goals.
The company is advancing the AUGMENTSM, OvaPrimeSM and OvaTureSM treatments for patients in need of new fertility treatment options.
The company indicated that its OvaPrime Treatment will be introduced into select international IVF Clinics by the end of 2015.
Amid the positive news, Wedbush Securities upgraded the stock from Neutral to Outperform and boosted the price target from $22 to $47.
OvaScience recently traded at $47.82, up 33.9 percent.
Latest Ratings for OVAS
|Aug 2016||JP Morgan||Maintains||Neutral|
|Jan 2016||Credit Suisse||Initiates Coverage on||Underperform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.